Grace Therapeutics develops reformulated medicines for rare diseases, led by an injectable form of nimodipine for patients with brain bleeding. It last closed at $1.72 on Nov 17, down 1.71% on the day. GRCE reports earnings on Mon, Feb 15, 2027.
GRCE · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 8% below its 20 day and 16% below its 50 day average. It is 57% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $1.71, and the nearest resistance the Pivot R1 at $1.77.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.5%/day
Key levels
$5.1852 week high+201.2%
$2.71200 day average+57.6%
$2.12100 day average+23.3%
$1.9950 day average+15.7%
$1.93Swing high (Nov 9)+12.2%
$1.8520 day average+7.6%
$1.77Pivot R1+2.9%
$1.72Last close
$1.71Pivot−0.6%
$1.67Swing low (Oct 26)−2.9%
$1.66Pivot S1−3.5%
$1.6552 week low−4.1%
Indicators
RSI (14)
35.31
Weak, oversold below 30
Neutral
MACD
-0.06
Below its signal line
Bearish
Stochastic
18.3
Near the bottom of its range
Oversold
ADX (14)
12.8
No clear trend
Williams %R
-81.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-191.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−3.4%
Change over 10 sessions
Bearish
ATR (14)
$0.11
Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumFading
StretchNear oversold
VolatilityNormal, 17.7%/day
Key levels
$5.1852 week high+201.2%
$2.71200 day average+57.6%
$2.12100 day average+23.3%
$1.9950 day average+15.7%
$1.93Swing high (Nov 9)+12.2%
$1.8520 day average+7.6%
$1.77Pivot R1+2.9%
$1.72Last close
$1.71Pivot−0.6%
$1.67Swing low (Oct 26)−2.9%
$1.66Pivot S1−3.5%
$1.6552 week low−4.1%
Indicators
RSI (14)
33.44
Weak, oversold below 30
Neutral
MACD
-0.26
Above its signal line
Bullish
Stochastic
16.6
Near the bottom of its range
Oversold
ADX (14)
34.1
Trending down
Williams %R
-90.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-175.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−22.5%
Change over 10 sessions
Bearish
ATR (14)
$0.30
Typical daily range, 17.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for GRCE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how GRCE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in GRCE in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRCE is in one of them and how their past GRCE trades turned out.
Grace Therapeutics is a pharmaceutical company based in Princeton, New Jersey, that develops reformulated versions of existing medicines for rare and orphan diseases. Its lead candidate, GTx-104, is an injectable form of nimodipine designed for intravenous delivery to patients with aneurysmal subarachnoid hemorrhage, a type of stroke. Its target customers include hospitals, physicians and patients. Its product candidates are still in development and have not yet been approved for sale.